Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Spotlight Group in connection with offer from Kriptown
Mandate

Vinge advises Spotlight Group in connection with offer from Kriptown

June 17, 2026 Capital Markets and Public M&A EU, Competition and Regulatory

Vinge is advising Spotlight Group AB (publ) in connection with Kriptown SAS having made a public cash takeover offer to the shareholders of Spotlight Group

The offer amounts to SEK 33 per share, which represents a premium of approximately 94 per cent relative to the closing price of Spotlight Group’s shares on the Spotlight Stock Market on the last trading day prior to the announcement of the offer. Shareholders controlling approximately 69 per cent of all shares and votes in Spotlight Group have unconditionally undertaken to accept the offer. Spotlight’s independent bid committee has recommended that the shareholders accept the offer.

Vinge’s team consists of Anders Strid and Edin Agic (Capital Markets) as well as Anna Palmérus and Fredrik Löwenclou (EU/Competition & Regulatory).

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026